Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Gamarra Luques, Carlos D ^a,b   Goyeneche, Alicia A ^a   Hapon, Maria B ^a,b   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; ANTINEOPLASTIC AGENT; DNA; HORMONE ANTAGONIST;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CANCER RELAPSE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DNA CONTENT; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; ENZYME MODIFICATION; HUMAN; HUMAN CELL; OVARY CANCER; TUMOR ESCAPE; CELL CYCLE; CELL CYCLE G1 PHASE; FEMALE; OVARY TUMOR; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DNA, NEOPLASM; FEMALE; G1 PHASE; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 84861476223     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-200     Document Type: Article

References (68)

1. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011, 11(10):719-725. 10.1038/nrc3144, 3380637, 21941283.
2. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010, 177(3):1053-1064. 10.2353/ajpath.2010.100105, 2928939, 20651229.
3. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9(6):415-428. 10.1038/nrc2644, 2814299, 19461667.
4. Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 2010, 3:8. 10.1186/1757-2215-3-8, 2856581, 20350313.
5. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3(7):502-516. 10.1038/nrc1123, 12835670.
6. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009, 9(3):167-181. 10.1038/nrc2583, 19238149.
7. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Sem Oncol 2006, 33(2 Suppl 6):S3-S11.
8. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334(1):1-6. 10.1056/NEJM199601043340101, 7494563.
9. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92(9):699-708. 10.1093/jnci/92.9.699, 10793106.
10. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21(17):3194-3200. 10.1200/JCO.2003.02.153, 12860964.
11. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354(1):34-43. 10.1056/NEJMoa052985, 16394300.
12. Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007, 13(11):3370-3379. 10.1158/1078-0432.CCR-07-0164, 2505183, 17545545.
13. Heikinheimo O, Lahteenmaki PL, Koivunen E, Shoupe D, Croxatto H, Luukkainen T, Lahteenmaki P. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987, 2(5):379-385.
14. Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem 1989, 32(1A):21-25.
15. Shoupe D, Mishell DR, Lahteenmaki P, Heikinheimo O, Birgerson L, Madkour H, Spitz IM. Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am J Obst Gynecol 1987, 157(6):1415-1420.
16. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL, Chrousos GP. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J Pharmacol Exp Ther 1987, 241(2):401-406.
17. Goyeneche AA, Seidel EE, Telleria CM. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs 2011, published ahead of print.
18. Conradie R, Bruggeman FJ, Ciliberto A, Csikasz-Nagy A, Novak B, Westerhoff HV, Snoep JL. Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex. FEBS J 2010, 277(2):357-367. 10.1111/j.1742-4658.2009.07473.x, 20015233.
19. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 2011, 11(1):207. 10.1186/1471-2407-11-207, 3125282, 21619605.
20. Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int 2009, 9:4. 10.1186/1475-2867-9-4, 2661041, 19222856.
21. Gamarra-Luques CD, Telleria CM. Enhancement of the lethality of platinum-based therapy by antiprogestin mifepristone in ovarian cancer. Cancer Epidemiol Bio Prev 2010, 19(10):Supplement 1, A113.
22. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002, 62(22):6559-6565.
23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70(2):440-446. 10.1158/0008-5472.CAN-09-1947, 20068163.
24. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58(3):621-681. 10.1124/pr.58.3.10, 16968952.
25. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003, 278(21):19245-19256. 10.1074/jbc.M208134200, 12637505.
26. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999, 27(10):1220-1223.
27. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 1998, 53(5):819-826.
28. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994, 69(2):299-306. 10.1038/bjc.1994.55, 1968703, 7905279.
29. Gately DP, Sharma A, Christen RD, Howell SB. Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Br J Cancer 1996, 73(1):18-23. 10.1038/bjc.1996.4, 2074296, 8554977.
30. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999, 274(44):31648-31654. 10.1074/jbc.274.44.31648, 10531373.
31. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990, 82(9):749-755. 10.1093/jnci/82.9.749, 1691303.
32. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1996, 37(5):463-471. 10.1007/s002800050413, 8599870.
33. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003, 63(6):1311-1316.
34. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006, 5(5):1197-1208. 10.1158/1535-7163.MCT-05-0445, 16731752.
35. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295(1):110-123. 10.1016/j.canlet.2010.02.019, 20236757.
36. Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 1999, 59(10):2425-2432.
37. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995, 1(6):599-606.
38. Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 1999, 5(4):767-774.
39. Kurata T, Tamura T, Shinkai T, Ohe Y, Kunitoh H, Kodama T, Kakinuma R, Matsumoto T, Kubota K, Omatsu H, Nishiwaki Y, Saijo N. Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. Jpn J Clin Oncol 2001, 31(3):93-99. 10.1093/jjco/hye022, 11336328.
40. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004, 57(6):756-763. 10.1111/j.1365-2125.2004.02082.x, 1884526, 15151521.
41. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31(15):1869-1883. 10.1038/onc.2011.384, 21892204.
42. Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 2007, 39(1):43-50. 10.1007/s10863-006-9059-5, 17318397.
43. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003, 278(11):9100-9106. 10.1074/jbc.M210284200, 12509415.
44. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584. 10.1038/nrc2167, 17625587.
45. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007, 7(1):3-18. 10.2174/187152007779314044, 17266502.
46. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23. 10.1016/j.ctrv.2006.09.006, 1855222, 17084534.
47. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev 2007, 107(5):1387-1407. 10.1021/cr068207j, 17455916.
48. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4(4):307-320. 10.1038/nrd1691, 15789122.
49. Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, Olofsson MH, Linder S. Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer 2009, 125(10):2450-2455. 10.1002/ijc.24627, 19670329.
50. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003, 3(3):193-203. 10.2174/1568009033481967, 12769688.
51. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996, 56(6):1253-1255.
52. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997, 57(5):870-874.
53. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2(1):72-79. 10.1038/nm0196-72, 8564846.
54. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005, 5(7):516-525. 10.1038/nrc1650, 15965493.
55. Erenpreisa J, Cragg MS. Cancer: a matter of life cycle?. Cell Biol Int 2007, 31(12):1507-1510. 10.1016/j.cellbi.2007.08.013, 17936649.
56. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol Int 2000, 24(9):621-633. 10.1006/cbir.2000.0557, 10964452.
57. Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R. Neosis: a novel type of cell division in cancer. Cancer Biol Ther 2004, 3(2):207-218.
58. Puig PE, Guilly MN, Bouchot A, Droin N, Cathelin D, Bouyer F, Favier L, Ghiringhelli F, Kroemer G, Solary E, Martin F, Chauffert B. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 2008, 32(9):1031-1043. 10.1016/j.cellbi.2008.04.021, 18550395.
59. Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM, Erenpreisa J. Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer 2006, 6:6. 10.1186/1471-2407-6-6, 1351196, 16401344.
60. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, Klymenko T, Ivanov A, Jascenko E, Scherthan H, Cragg M, Erenpreisa J. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 2010, 316(13):2099-2112. 10.1016/j.yexcr.2010.04.030, 20457152.
61. Erenpreisa J, Salmina K, Huna A, Kosmacek EA, Cragg MS, Ianzini F, Anisimov AP. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell Biol Int 2011, 35(7):687-695. 10.1042/CBI20100762, 21250945.
62. Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 2009, 34(3):743-755. 2690705, 19212679.
63. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, Zhou L, Shen J, Han G, Wang XJ, Thorburn J, Thorburn A, Jimeno A, Raben D, Bedford JS, Li CY. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011, 17(7):860-866. 10.1038/nm.2385, 3132290, 21725296.
64. Galluzzi L, Kepp O, Kroemer G. Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy. Oncogene 2011, published ahead of print.
65. Kvinlaug BT, Huntly BJ. Targeting cancer stem cells. Expert Opin Ther Targets 2007, 11(7):915-927. 10.1517/14728222.11.7.915, 17614760.
66. Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010, 29(35):4905-4913. 10.1038/onc.2010.245, 2933510, 20581869.
67. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006, 24(8):727-733. 10.1080/07357900601062339, 17162554.
68. Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin Pharmacother 2008, 9(14):2459-2472. 10.1517/14656566.9.14.2459, 18778184.